Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch önlein) with aggressive nephritis.
CONCLUSIONS: RTX proved to be effective and safe for induction and maintenance of long-lasting remission in severe IgAV with aggresive renal involvement. Data also suggest that RTX can be indicated not only for refractory cases, but can be also proposed as a first line therapy.
PMID: 32441647 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Glomerulonephritis | Heart | Henoch-Schonlein Purpura | Nephritis | Proteinuria | Rheumatology | Rituxan | Study | Urology & Nephrology | Vasculitis